References

The immunology of type 1 diabetes

10.1038/s41577-023-00985-4 · 2024 · External reference

Cracking the type 1 diabetes code: genes, microbes, immunity, and the early life environment

10.1111/imr.13362 · 2024 · External reference

Trends in the incidence of type 1 diabetes in European children and adolescents from 1994 to 2022: a systematic review and meta-analysis

10.1155/2024/2338922 · 2024 · External reference

Type 1 diabetes glycemic management: insulin therapy, glucose monitoring, and automation

10.1126/science.abg4502 · 2021 · External reference

Factors associated with early remission of type I diabetes in children treated with cyclosporine

10.1056/nejm198803173181103 · 1988 · External reference

Teplizumab and β-cell function in newly diagnosed type 1 diabetes

10.1056/nejmoa2308743 · 2023 · External reference

B-lymphocyte depletion with rituximab and β-cell function: two-year results

10.2337/dc13-0626 · 2014 · External reference

Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked, controlled trial

10.2337/dc22-2200 · 2023 · External reference

Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective

10.1093/immadv/ltad007 · 2023 · External reference

Regulatory T cells contribute to diabetes protection in lipopolysaccharide-treated non-obese diabetic mice

10.1111/j.1365-3083.2011.02627.x · 2011 · External reference

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

10.1016/j.immuni.2008.03.016 · 2008 · External reference

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

10.1084/jem.20100209 · 2010 · External reference

The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

10.1038/nri3823 · 2015 · External reference

A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells

10.1016/j.immuni.2008.11.014 · 2009 · External reference

Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis

10.1056/nejmoa1105143 · 2011 · External reference

Interleukin-2 and regulatory T cells in graft-versus-host disease

10.1056/nejmoa1108188 · 2011 · External reference

A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases

10.1016/j.ebiom.2023.104539 · 2023 · External reference

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

10.1016/s2213-8587(13)70113-x · 2013 · External reference

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

10.1016/j.jaut.2015.01.001 · 2015 · External reference

Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a phase I/II randomised, double-blind, placebo-controlled, dose-finding study

10.1007/s00125-020-05200-w · 2020 · External reference

Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial

10.1136/annrheumdis-2019-215396 · 2020 · External reference

Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial

10.1136/ard-2022-222501 · 2022 · External reference

The universal effects of low-dose interleukin-2 across 13 autoimmune diseases in a basket clinical trial

10.1016/j.jaut.2024.103172 · 2024 · External reference

Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes

10.1371/journal.pone.0026471 · 2011 · External reference

Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial

10.1016/s0140-6736(25)00262-4 · 2025 · External reference

Anti-inflammatory therapy with low-dose IL-2 in acute coronary syndromes: a randomized phase 2 trial

10.1038/s41591-025-04090-y · 2026 · External reference

Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2

10.1016/j.jaci.2018.06.006 · 2018 · External reference

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

10.1016/s0140-6736(11)60931-8 · 2011 · External reference

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function

10.2337/db12-0049 · 2012 · External reference

Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes

10.2337/db13-0214 · 2013 · External reference

Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association

10.2337/dc15-1419 · 2015 · External reference

C-peptide levels in subjects followed longitudinally before and after type 1 diabetes diagnosis in TrialNet

10.2337/dc19-2288 · 2020 · External reference

Inducible protein degradation reveals inflammation-dependent function of the Treg cell lineage-defining transcription factor Foxp3

10.1126/sciimmunol.adr7057 · 2025 · External reference

Emerging immunotherapies for disease modification of type 1 diabetes

10.1007/s40265-025-02150-8 · 2025 · External reference

Long-term results of early cyclosporin therapy in juvenile IDDM

10.2337/diab.45.1.101 · 1996 · External reference

Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group

10.1016/1056-8727(92)90016-e · 1992 · External reference

An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

10.1056/nejmoa1902226 · 2019 · External reference